Lucid Diagnostics develops a non-invasive, office based diagnostic test for biomarkers to esophageal cancer.
LUCID DIAGNOSTICS INC. has raised $18.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
LUCID DIAGNOSTICS INC.'s investors include National Institutes of Health.
LUCID DIAGNOSTICS INC. is headquartered in New York, United States.
Lucid Diagnostics develops a non-invasive, office based diagnostic test for biomarkers to esophageal cancer.
LUCID DIAGNOSTICS INC. is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LUCID DIAGNOSTICS INC. — Funding & Investors." VCBacked, April 23, 2026, https://www.vcbacked.co/company/lucid-diagnostics-inc. Accessed October 16, 2026.
VCBacked. (2026). LUCID DIAGNOSTICS INC. — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/lucid-diagnostics-inc
{{cite web |title=LUCID DIAGNOSTICS INC. — Funding & Investors |url=https://www.vcbacked.co/company/lucid-diagnostics-inc |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated